Antioxidant effects of simvastatin in patients with coronary heart disease and dyslipidemia
https://doi.org/10.15829/1728-8800-2012-6-16-22
Abstract
Aim. To investigate the effects of simvastatin therapy on antioxidant enzyme activity and the correction of disturbed antioxidant status in patients with coronary heart disease (CHD) – post-infarction cardiosclerosis (PICS) – in combination with dyslipidemia (DLP).
Material and methods. The study included 132 CHD patients with PICS and 20 healthy controls. All participants underwent the measurement of plasma levels of lipids, lipid peroxidation (LP) products – diene conjugates (DC) and 2-thiobarbituric acid reagents (TBAR), antioxidant enzymes – glutathione peroxidase (GP) and superoxide dismutase (SOD) in red blood cells, plasma activity of the antioxidant ceruloplasmin/transferrin system (AOS CP/TF) (electron paramagnetic resonance method), and 24-hour Holter monitoring of electrocardiogram (ECG).
Results. The three-month simvastatin therapy (20 mg/day), as a component of the complex cardiac treatment, demonstrated its antioxidant effects and antiperoxidation activity in 60% of CHD patients. The subsequent therapy with 2-ethyl-6-methyl-3-hydroxypyridine sulphate (ES; 375 mg/day) and ubidecarenone (30 mg/ day) normalised the parameters of LP-antioxidant defence (AOD) and the levels of hepatic transaminases. Plasma AOS CP/TF activity inversely correlated with the duration of myocardial ischemia in CHD patients (r=-0,34; p=0,004).
Conclusion. To optimise the treatment of atherogenic DLP in simvastatin-treated CHD patients, ubidecarenone and ES could be used to improve the LP-AOD parameters.
About the Authors
N. E. Artamoshina
Polyclinic No. 5, Russian Federation President’s Administration
Russian Federation
Russian Federation
K. Yu. Bondar
Moscow State Medico-Stomatological University
Russian Federation
Russian Federation
O. L. Belaya
Moscow State Medico-Stomatological University
Russian Federation
Russian Federation
L. M. Bayder
N.M. Emmanuel Institute of Biochemical Physics, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
Z. V. Kuropteva
N.M. Emmanuel Institute of Biochemical Physics, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Belaya O.L., Bayder L.М., Кuropteva Z.V. Study of antioxidant system ceruloplasmin/transferrin blood and plasma activity in stable coronary heart disease patients by electronic spin resonance. Questions of biological, medical and pharmaceutical chemistry 2006; 4: 46-9. Russian (Белая О.Л., Байдер Л.М., Куроптева З.В. Изучение активности антиоксидантной системы церулоплазмин/трансферрин в крови и плазме у больных ИБС со стабильной стенокардией II и III ФК методом электронного парамагнитного резонанса. Вопр биол мед и фармацевт хим 2006; 4: 46-9).
2. Belaya O.L., Bayder L.М., Кuropteva Z.V. Study of antioxidant mexydol effect on contents of plasma proteins ceruloplasmin and transferrin and lipid peroxidation in stable coronary heart disease patients with dyslipidemia. News of medical-biological sciences 2005; 2: 71-6. Russian (Белая О.Л., Байдер Л.М., Куроптева З.В. Изучение действия антиоксидантного препарата мексидол на содержание плазменных белков церулоплазмина и трансферрина и процессы перекисного окисления липидов у больных стабильными формами ИБС с дислипидемией. Нов мед-биолог наук 2005; 2: 71-6).
3. Burlakova E.B. Bioantioxidants: yesterday, today, tomorrow. In: Panorama of modern chemistry of Russia. Chemical and biological kinetic, new horizonts. Moscow: Chemistry; 2005.2.pp.10-46. (Russian Бурлакова Е.Б. Биоантиоксиданты: вчера, сегодня, завтра. Панорама современной химии России. Химическая и биологическая кинетика, новые горизонты. М. «Химия» 2005; 2: 10-46).
4. Golikov A.P., Polumiskov V.Yu., Mikhin V.P., et al. Antioxidantscytoprotectors in cardiology. Cardiovascular Therapy and Prevention 2004; 6: 66-74. Russian (Голиков А.П., Полумисков В.Ю., Михин В.П. и др. Антиоксиданты-цитопротекторы в кардиологии. Кардиоваскулярная терапия и профилактика 2004; 6: 66-74).
5. Gorokhova S.G. Coenzyme Q10 in adjuvant therapy of cardiovascular disease. Russian Medical Journal 2008;16; 11: 558-1560. Russian (Горохова С.Г. Коэнзим Q10 в адъювантной терапии сердечно-сосудистых заболеваний. РМЖ 2008;16 (11): 1558-60).
6. Drinitzina S.V., Zateischikov D.A. Antioxidant properties of statins. Cardiology 2005; 45; 4:65-72. Russian (Дриницына С.В., Затейщиков Д.А. Антиоксидантные свойства статинов. Кардиология 2005; 45; 4: 65-72).
7. Zakirova А.N. Clinical and haemodinamic effects of antioxidant ceruloplasmin in coronary heart disease patients. Cardiology 1995; 3:.33-35. Russian (Закирова А.Н. Клинико-гемодинамические эффекты антиоксиданта церулоплазмина у больных ИБС. Кардиология 1995; 3: 33-5).
8. Kozlov А.V., Sergienko V.I., Vladimirov Yu.A. et al. Antioxidant system ceruloplasmin/transferrin in experimental hypercholesterinemia. Bulletin of Experimental Biology and Medicine 1984;.12: 668-671. Russian (Козлов А.В., Сергиенко В.И., Владимиров Ю.А., Азизова О.А. Антиоксидантная система трансферрин – церулоплазмин при экспериментальной гиперхолестеринемии. Бюлл экспер биол 1984;12: 668-71).
9. Lankin V.Z., Tikhaze А.К., Belenkov Yu.N. Antioxidants in complex therapy of atherosclerosis: pro et contra. Cardiology 2004; 2: 72-81. Russian (Ланкин В.З., Тихазе А.К., Беленков Ю.Н. Антиоксиданты в комплексной терапии атеросклероза: pro et contra. Кардиология 2004; 2: 72-81).
10. Podoprigorova V.G. ESR-spectroscopia of antioxidant system ceruloplasmin/transferrin in clinical practice. Materials of 4-th National scientific and practical Conference with international participation «Reactive oxygen species, nitric oxide, antioxidants and human health».Smolensk 2005; pp.82-3. Russian (Подопригорова В.Г. ЭПР-спектроскопия антиоксидантной системы церулоплазмин/трансферрин в клинической практике. Сб. трудов «Активные формы кислорода, оксид азота, антиоксиданты и здоровье человека». 4-ая национальная научно-практическая конференция с международным участием. Смоленск 2005; 82-3).
11. Smirnov L.D. Structure, pharmacologic properties and medical use of heteroaromatic antioxidants. In: Panorama of modern chemistry of Russia. Chemical and biological kinetic, new horizonts. Moscow: Chemistry; 2005. 2.pp.112-7. Russian (Смирнов Л.Д. Структура, фармакологические свойства и медицинское применение гетероароматических антиоксидантов. Панорама современной химии России. Химическая и биологическая кинетика, новые горизонты. М. «Химия» 2005; 2: 112-7).
12. Deedwania P., Stone P.H., Merz C.N.B., et al. Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease: Results of the Study Assessing Goals in the Eldery (SAGE). Circulation 2007; 115: 700-7.
13. Mortensen S., Leth A., Agner E, et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997; 18: 137-44.
14. Palomaki A., Malminiemi K., Solakivi T. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. J Lipid Res 1998;39: 1430-7.
15. Wagner A.H., Kohler T., Ruckschloss U., et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-6.
Review
For citations:
Artamoshina N.E., Bondar K.Yu., Belaya O.L., Bayder L.M., Kuropteva Z.V. Antioxidant effects of simvastatin in patients with coronary heart disease and dyslipidemia. Cardiovascular Therapy and Prevention. 2012;11(6):16-22. (In Russ.) https://doi.org/10.15829/1728-8800-2012-6-16-22
Views:
564
Email this article 
